US Stock MarketDetailed Quotes

NTLA Intellia Therapeutics

Watchlist
  • 12.470
  • -0.330-2.58%
Close Jan 7 16:00 ET
  • 12.630
  • +0.160+1.28%
Post 20:01 ET
1.27BMarket Cap-2.29P/E (TTM)

Intellia Therapeutics Key Stats

Intellia Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 11 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 9.361M--
--2024/Q4-- / 8.895M--
Nov 7, 20242024/Q39.111M / 7.499M--
Aug 8, 20242024/Q26.957M / 18.249M--
May 9, 20242024/Q128.935M / 9.065M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 9.361M--
--2024/Q4-- / 8.895M--
Nov 7, 20242024/Q39.111M / 7.499M--
Aug 8, 20242024/Q26.957M / 18.249M--
May 9, 20242024/Q128.935M / 9.065M--

Unlock Free Earnings Estimates

Intellia Therapeutics Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Jan 7, 2025

Strong Buy

  • Buy

    80.95%
  • Hold

    19.05%
  • Sell

    0.00%

Price Target

No Data